ClinicalTrials.gg
Not yet recruitingNCT07457294Updated Mar 9, 2026

1% Clascoterone Cream for the Treatment Acne Vulgaris

A Phase 3 interventional study of 1% Clascoterone Cream and Placebo in Acne Vulgaris, sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
692
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Planned enrollment
3rd of 19
692 · median 50
Started
2026
with 3 others
Phase 3
5 of 19
2 open now
Registered
16th of 19
by date
Lead sponsor
3 of 19
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 5 in phase 3, and was the 16th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.

Target population: Participants aged ≥12 years with moderate to severe acne vulgaris who meet the inclusion criteria and none of the exclusion criteria.

Treatment: The investigational group will receive 1% Clascoterone Cream, and the control group will receive placebo. Approximately 1 g of the cream will be applied evenly to the entire face twice daily (morning and evening) for 12 weeks.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are able to understand and comply with the protocol, voluntarily participate in the study, and sign the written form (ICF); for a participant aged \<18 years, the written ICF must be co-signed by the minor participant and a parent or legal guardian based on informed consent;
  • Age ≥12 years at the time of ICF signing, regardless of gender;
  • Diagnosis of moderate to severe acne vulgaris (including the nose) at screening and randomization, with an IGA score of 3 or 4, and facial lesions meeting the following criteria: 30-75 inflammatory lesions (papules, pustules, and nodules) and 30-100 non-inflammatory lesions (open and closed comedones);
  • Participants have used the same brand and type of skin and hair care products for at least 2 weeks prior to randomization and agree to continue the current products and regimen during the study period;
  • Female participants of (and their male partners) and male participants (and their female partners) must use highly effective throughout the study period and for at least 3 months after the last dose of the study drug . Participants must have no plans for conception, sperm donation, or egg donation throughout the study period and for at least 3 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Participants have more than 2 facial nodules at screening or randomization;
  • Participants have facial cysts at screening or randomization;
  • Participants have conditions at screening or randomization, which may interfere with the investigator's clinical assessments, including but not limited to: 1) Other facial dermatoses: specific types of acne (e.g., nodulocystic acne, acne conglobata, acne fulminans, etc.), secondary acne (e.g., drug-induced acne, mechanical acne, occupational acne, chloracne, etc.), or other facial rashes due to different conditions (e.g., rosacea, seborrheic dermatitis, solar dermatitis, lupus miliaris disseminatus faciei, psoriasis, eczema, etc.); 2) Facial skin or hair conditions that may interfere with clinical assessments (e.g., prominent beard, sideburns, whiskers, etc.);
  • Participants have systemic diseases with associated skin lesions: e.g., inflammatory bowel disease (Crohn's disease and ulcerative colitis), SAHA syndrome (seborrhea-acne-hirsutism-androgenetic alopecia syndrome), PCOS syndrome (polycystic ovary syndrome), SAPHO syndrome (synovitis-acne-pustulosis-hyperostosis-osteomyelitis), PAPA syndrome (pyogenic sterile arthritis-pyoderma gangrenosum-acne syndrome), hyperandrogenism-insulin resistance-acanthosis nigricans syndrome, congenital adrenal hyperplasia, etc.;
  • Prior use of the topical acne medications or therapies or Use of the systemic medications;
  • Use of skin care products with anti-acne efficacy within 2 weeks prior to randomization;
  • Participants have any serious or unstable medical condition that, in the investigator's judgment, may affect the participant's safety during the study and/or impede study completion, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, or psychiatric disorders.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
692 participants (estimated)

Study arms

  • Experimental
    1% Clascoterone Cream

    Drug: 1% Clascoterone Cream

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 1% Clascoterone Cream applied topically to affected areas twice daily for the duration of the study.

  • DrugPlacebo

    Placebo cream, matching the 1% Clascoterone Cream in appearance, texture, and scent, applied topically to affected areas twice daily for the duration of the study.

06

What researchers measure

Primary outcomes

  1. P1: Proportion of participants achieving "success" at Week 12 ("success" is defined as an Investigator's Global Assessment (IGA) score of 0 or 1, with at least a 2-point reduction from baseline);

    Time frame: Week 12

Secondary outcomes

  1. Proportion of participants achieving "success" at Week 4 and Week 8

    Time frame: Week 4 and Week 8

  2. Absolute change from baseline in NILC at Week 4 and Week 8

    Time frame: Week 4 and Week 8

  3. Absolute change from baseline in ILC at Week 4 and Week 8

    Time frame: Week 4 and Week 8

  4. Absolute change from baseline in total lesion count (inflammatory and non-inflammatory lesions) at Week 4, Week 8, and Week 12

    Time frame: Week 4, Week 8, and Week 12

  5. Percent change from baseline in total lesion count at Week 4, Week 8, and Week 12

    Time frame: Week 4, Week 8, and Week 12

  6. Percent change from baseline in ILC at Week 4, Week 8, and Week 12

    Time frame: Week 4, Week 8, and Week 12

  7. Percent change from baseline in NILC at Week 4, Week 8, and Week 12

    Time frame: Week 4, Week 8, and Week 12

  8. Safety: Incidence of adverse events

    Time frame: Week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Due to the nature of the study and privacy concerns, de-identified individual participant data will not be made available to external researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Aug 2028, 27 months later.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's planned 27 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 9, 2026
StartEst.
May 4, 2026
Primary completionEst.
Aug 7, 2028
CompletionEst.
Feb 7, 2029
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457294
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
May 4, 2026 (estimated)
Primary completion
Aug 7, 2028 (estimated)
Completion
Feb 7, 2029 (estimated)
Last update
Mar 9, 2026

Study contacts

Jie Wang
Contact
wangjie13@3sbio.com
+86 13140705482

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion